Cytopenia Clinical Trials

2 recruiting

Frequently Asked Questions

Common questions about Cytopenia clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 118 of 18 trials

Recruiting
Phase 2

Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia

Chronic Myelomonocytic LeukemiaRecurrent LymphomaRecurrent Diffuse Large B-Cell Lymphoma+5 more
Mayo Clinic80 enrolled4 locationsNCT03418038
Recruiting
Early Phase 1

Single Arm Romiplostim to Prevent CIT

Ewings SarcomaChemotherapy Induced Thrombocytopenia
Children's Hospital Medical Center, Cincinnati26 enrolled2 locationsNCT07048249
Recruiting
Phase 2

A Phase 2 Study Evaluating Olutasidenib in Patients With IDH1-mutated Clonal Cytopenia of Undetermined Significance and Lower-risk Myelodysplastic/Syndromes/Chronic Myelomonocytic Leukemia.

Myelodysplastic SyndromesChronic Myelomonocytic LeukemiaClonal Cytopenia of Undetermined Significance
M.D. Anderson Cancer Center15 enrolled1 locationNCT06566742
Recruiting

Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective

Streptococcus PneumoniaeMalariaMeningitis+55 more
Institut Pasteur du Cambodge10,000 enrolled1 locationNCT07358910
Recruiting
Not Applicable

Home Blood Transfusions

Acute Myeloid LeukemiaHematologic MalignancyMyelodysplastic Syndromes+1 more
Thomas Jefferson University30 enrolled1 locationNCT07121140
Recruiting
Phase 2

Herombopag Treated T-DM1 Induced Platelet Reduction

Thrombocytopenia
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University56 enrolled1 locationNCT07257809
Recruiting
Phase 2

177Lu-PSMA-617 in Metastatic Castration Resistant Prostate Cancer (mCRPC) With Bone Marrow Involvement and Cytopenia

Metastatic Castration-resistant Prostate CancerThrombocytopeniaAnemia+1 more
M.D. Anderson Cancer Center40 enrolled1 locationNCT07025512
Recruiting

Clonal Hematopoiesis and Therapy-Emergent Myeloid Neoplasms in Patients With Cancers, CHANCES Study

Ovarian CarcinomaRecurrent Ovarian CarcinomaRecurrent Malignant Solid Neoplasm+7 more
University of Washington2,000 enrolled1 locationNCT06295965
Recruiting
Early Phase 1

Safety Study of CC312 in Autoimmune Disease Patients

Rheumatoid Arthritis (RA)Autoimmune Hemolytic AnemiaSystemic Lupus Erythematosus (SLE)+3 more
CytoCares Inc18 enrolled1 locationNCT06888960
Recruiting

Conception of a Diagnosis, Prognosis and Therapeutic Decision Tool for Patients With Autoimmunity and Inflammation

Autoimmune HepatitisSystemic Lupus ErythematosusHemophagocytic Lymphohistiocytoses+17 more
Institut National de la Santé Et de la Recherche Médicale, France500 enrolled1 locationNCT04902807
Recruiting
Phase 2

AlloSCT for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha/Beta T Cell and CD19+ B Cell Depletion

Hodgkin LymphomaNon-Hodgkin LymphomaAcute Leukemia+6 more
Mitchell Cairo20 enrolled1 locationNCT04099966
Recruiting

Shwachman-Diamond Syndrome Global Patient Survey and Partnering Platform

Myelodysplastic SyndromesShwachman-Diamond SyndromeSDS+24 more
Shwachman-Diamond Syndrome Alliance Inc8,000 enrolled1 locationNCT06999954
Recruiting
Phase 2

Telitacicept for the Treatment of Connective Tissue Disease-associated Thrombocytopenia

ThrombocytopeniaConnective Tissue Diseases
Beijing Hospital296 enrolled23 locationsNCT05998759
Recruiting
Phase 1

UCMSC-Exo for Chemotherapy-induced Myelosuppression in Acute Myeloid Leukemia

Acute Myeloid LeukemiaThrombocytopeniaNeutropenia+3 more
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology9 enrolled1 locationNCT06245746
Recruiting
Early Phase 1

Apixaban in Thrombocytopenia

ThrombocytopeniaDeep Vein ThrombosisPulmonary Embolism and Thrombosis+1 more
Rushad Patell30 enrolled1 locationNCT06886516
Recruiting
Phase 2

Avatrombopag in the Treatment of Pediatric Immune Thrombocytopenia

TreatmentImmune Thrombocytopenia
Institute of Hematology & Blood Diseases Hospital, China60 enrolled1 locationNCT06281327
Recruiting
Phase 2

Repurposing Metformin As a Leukemia-preventive Drug in CCUS and LR-MDS

Myelodysplastic NeoplasmPreleukemiaCytopenia+1 more
Kirsten Grønbæk40 enrolled1 locationNCT04741945
Recruiting

OBS'CEREVANCE: French Cohort of Pediatric Autoimmune Cytopenia

Immune ThrombocytopeniaAutoimmune Hemolytic AnemiaEvans Syndrome
University Hospital, Bordeaux3,500 enrolled9 locationsNCT05937828